ストックスクリーナーアプリを入手
17.77
3.32%
-0.61
前日終値:
$18.38
開ける：
$18.335
24時間の取引高:
1.07M
Relative Volume:
0.81
時価総額：
$1.98B
収益：
$-665.00K
当期純損益:
$-150.11M
株価収益率:
-11.79
EPS:
-1.5071
ネットキャッシュフロー:
$-124.53M
1週間 パフォーマンス:
-2.74%
1か月 パフォーマンス:
+32.02%
6か月 パフォーマンス:
+45.54%
1年 パフォーマンス:
+140.46%
1日の値動き範囲:
$17.15
$18.34
1週間の範囲:
$17.15
$18.61
52週間の値動き範囲:
$7.21
$19.15
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-682-0917
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
17.77 | 1.98B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-03 | 開始されました | Stifel | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr
Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr
Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com India
[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com
Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView
AMLX Forecast — Price Target — Prediction for 2027 - TradingView
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa
AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa
Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - BioSpace
Amylyx presents early safety data for ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria
Amylyx presents early safety data for ALS drug candidate AMX0114 - Investing.com
Amylyx says ALS drug AMX0114 showed no serious safety issues - Stock Titan
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen - Moomoo
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR - Moomoo
Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
3.42%
0.81%
大文字化:
|
ボリューム (24 時間):